A COST-EFFECTIVENESS STUDY OF SECOND-LINE TREATMENT IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER IN SPAIN

被引：0
|
作者：
Arlandis, S.
Castro, D.
Errando, C.
Fernandez, E.
Jimenez, M.
Gonzalez, P.
Crespo, C.
Stauble, F.
Rodriguez, J. M.
机构：
[1] Hosp Univ La Fe, Valencia, Spain
[2] Hosp Clin, Santa Cruz De Tenerife, Spain
[3] Fundacio Puigvert, Barcelona, Spain
[4] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[5] Medtron Iber SA, Madrid, Spain
[6] Oblikue Consulting, Barcelona, Spain
[7] Medtron Int Trading Sarl, Suiza, Spain
来源：
GACETA SANITARIA | 2009年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：200 / 201
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS STUDY OF SECOND LINE THERAPIES IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER IN SPAIN
    Arlandis, S.
    Castro, D.
    Errando, C.
    Fernandez, E.
    Jimenez, M.
    Gonzalez, P.
    Crespo, C.
    Stauble, F.
    Rodriguez, J. M.
    Brosa, M.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 136 - 136
  • [2] Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain
    Peral, Carmen
    Cordido, Fernando
    Gimeno-Ballester, Vicente
    Mir, Nuria
    Sanchez-Cenizo, Laura
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (01) : 105 - 114
  • [3] Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer
    Sarfaty, Michal
    Hall, Peter
    Chan, Kelvin K.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
    Sarfaty, Michal
    Hall, Peter S.
    Chan, Kelvin K. W.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    [J]. EUROPEAN UROLOGY, 2018, 74 (01) : 57 - 62
  • [5] COST-EFFECTIVENESS ANALYSIS OF SECOND-LINE PHARMACOLOGICAL TREATMENTS OF ACROMEGALY IN SPAIN
    Peral, C.
    Cordido, F.
    Gimeno, V
    Sanchez-Cenizo, L.
    Mir, N.
    Parrondo, J.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A557 - A558
  • [6] Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer
    Chang, Sam S.
    [J]. JOURNAL OF UROLOGY, 2019, 202 (06): : 1095 - 1096
  • [7] Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder
    Leong, Randall K.
    de Wachter, Stephan G. G.
    Joore, Manuela A.
    van Kerrebroeck, Philip E. V.
    [J]. BJU INTERNATIONAL, 2011, 108 (04) : 558 - 564
  • [8] COST-EFFECTIVENESS OF SECOND-LINE VASOPRESSORS FOR THE TREATMENT OF SEPTIC SHOCK
    Lam, Simon
    Barreto, Erin
    Scott, Rachael
    Kashani, Kianoush
    Khanna, Ashish
    Bauer, Seth
    [J]. CRITICAL CARE MEDICINE, 2020, 48
  • [9] COST-EFFECTIVENESS OF PHARMACOLOGIC TREATMENT OF OVERACTIVE BLADDER
    Malone, D. C.
    Armstrong, E. P.
    Bui, C.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A155 - A155
  • [10] Cost-effectiveness of second-line vasopressors for the treatment of septic shock
    Lam, Simon W.
    Barreto, Erin F.
    Scott, Rachael
    Kashani, Kianoush B.
    Khanna, Ashish K.
    Bauer, Seth R.
    [J]. JOURNAL OF CRITICAL CARE, 2020, 55 : 48 - 55
12345